

Q4 2021 Conference Call

February 22, 2022

Rice Powell

Chief Executive Officer &
Chairman of the Management Board

Helen Giza

Chief Financial Officer &
Chief Transformation Officer



Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).


Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.



■ FY 2021 | Achieving Targets in a Challenging Year



- **Financial targets for FY 2021 achieved**
- Business development significantly **impacted by COVID-19** in 2021, effects are **expected to continue** into 2022
- **Decline in excess mortality** in the fourth quarter
- 25th consecutive **dividend increase** to 1.35 EUR proposed
- Implementation of **strategic priorities** on track

AGENDA



1 Strategy Update

2 Medical Update

3 Business Update

4 Financials


5 Outlook

■ Key Drivers for our Core Dialysis Business remain intact

Addressing global health care challenges



Global population aged 65+¹



HYPERTENSION

One out of four people worldwide has hypertension!

People living with hypertension²



DIABETES

+280%

People living with diabetes³

151 million

2000

578 million

2030



DIALYSIS PATIENTS

+460%

People on maintenance dialysis⁴

1.07 million

2000

>6 million

2030

¹ United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, Volume II: Demographic Profiles (ST/ESA/SER.A/427) ² WHO Global Health Observatory (people >18 years of age) | ³ IDF Diabetes Atlas 2019 (9th edition) | ⁴ FME Long Range Patient Projection 2020

■ Execution on Strategy 2025

RENAL CARE CONTINUUM


Dialysis Business, Value-based Care models, expansion along the renal patient journey in CKD and transplant to further enhance patient experience

Expand Service and Product portfolio and establish digital care models

COMPLEMENTARY ASSETS

Leverage competencies and build new capabilities for the future of medical care models

New patient-focused therapy offerings in renal care and beyond



CORE - DIALYSIS PRODUCTS AND SERVICES

Dialysis Services, Dialysis Products

Leverage expertise in Services, MedTech and Pharma to maximize impact of vertical integration

CRITICAL CARE

Leverage expertise to address critical acute health challenges

Build on extracorporeal physiological multi-organ support

Capturing Growth Potential



Driving Value-based Care

- Manage care for around 80,000 CKD and ESRD patients in private and public Value-based Care arrangements
- Leverage longstanding experience in Value-based Care and largest database of CKD patients in the industry
- For 2022 around USD 1.1 billion of revenue and more than USD 6 billion of Medical Costs Under Management are expected



Expanding Home dialysis

New aspirational target set for expansion of home dialysis:

25% of dialysis treatments in the U.S.
to be performed in a home setting **by 2025.**

■ Key ESG Achievements



Patients

78% of our patients would highly recommend our services



>2,000 improvements made to our dialysis machines, dialyzers, and solution products

0.1 quality audit score achieved, well below 1.0 target threshold of findings per audit



Employees

74% of employees participated in 2021 engagement survey – an increase of 6 percentage points



71% of our employees feel a sense of belonging at work



Planet



>100 environmental initiatives contributed to reduction of GHG, water use and waste at manufacturing sites

All **40** producing sites linked with new digital eco-performance platform



Responsible business



Almost **90%** of employees completed compliance training



>90% of internal audits covered ESG aspects

About **29,000** third parties assessed for compliance risks

■ Global Climate Targets

In line with a 1.5°C science-based scenario

2030

**50%
CO2 emissions
reduction**

2040

**Climate
neutral**

Scope 1 and 2 emissions, business as is | Base year: 2020 (769kt CO2e)

Levers to achieve targets

Renewable energy sourcing complemented by

- Process optimization
- Energy efficiency measures
- Renewable energy generation
- Technology assessment
- Renewable energy certificates for transition

Milestones


- 100% renewable electricity sourcing in the U.S. and Canada and >80% in the EU by 2025
- Continuous review of scope 3 emissions impact for inclusion in targets

■ FME25 | Future Operating Model to enable Strategy 2025

Global Operating Model



Strategy 2025



AGENDA

1 **Strategy Update**


2 **Medical Update**

3 **Business Update**

4 **Financials**

5 **Outlook**

■ FY 2021 | Delivering Care of consistent Quality



+2% Clinics
4,171



+0% Patients
345,425



(1%) Treatments
52,871,887



Quality remains
on a consistently
high level

Clinics, patients and treatments as of December 31, 2021

■ FY 2021 | Treatment Quality on high Level


	North America		EMEA		Latin America		Asia-Pacific	
% of patients	Q4 2021	Q4 2020	Q4 2021	Q4 2020	Q4 2021	Q4 2020	Q4 2021	Q4 2020
Kt/V ≥ 1.2	97	97	93	93	93	91	94	94
Hemoglobin = 10–12 g/dl	72	71	82	82	49	48	51	52
Calcium = 8.4–10.2 mg/dl	84	81	81	78	76	73	70	72
Albumin ≥ 3.5 g/dl	83	80	89	90	90	89	88	91
Phosphate ≤ 5.5 mg/dl	56	59	79	80	75	76	67	64
Patients without catheter (after 90 days)	78	79	76	77	78	78	80	81
in days								
Days in hospital per patient year	10.0		9.7		7.5		7.7	
					4.0		4.0	
					4.0		3.5	




Definitions of quality parameters cf. 2020 Annual Report, section "Non-Financial Group Report". Going forward, FME will be reporting days in hospital per patient year on a global basis (starting with the publication of the Non-Financial Report 2021).

■ Confirmed COVID-19 Cases since January 2020

General population cases globally




FME patient cases globally



► Rolling 7-day average of daily new confirmed COVID-19 cases. Left chart: global data of John Hopkins University CSSE COVID-19 Data (February 14, 2022), right chart: FME data based on internal sources

■ Decline in global Excess Mortality

Quarterly Excess mortality vs. 2019 base



- Lower COVID-19-related excess deaths in Q4 despite the spread of Omicron variant
- LTM excess mortality amounts to 9,753
- Total number of excess deaths vs. 2019 base since Q1 2020 amounts to 20,132

Historical excess mortality updated for late entries.

AGENDA

1 **Strategy Update**

2 **Medical Update**

3 **Business Update**

4 **Financials**

5 **Outlook**

■ Q4 2021 | Revenue Growth despite COVID-19

	Q4 2021 € million	Q4 2020 € million	Growth in %	Growth in %acc
Revenue	4,647	4,400	6	3
Operating income	449	462	(3)	(7)
Operating income excl. special items ¹	492	657	(25)	(28)
Net income	229	177	29	23
Net income excl. special items ¹	263	372	(29)	(32)

- Revenue growth in both Health Care Services and Health Care Products
- Negative effects of COVID-19 continued to accumulate
- Inflationary cost increases and higher personnel expense
- Tailwind from FX effects



1 Special items relate to costs associated with FME25 program in 2021 and Latin America impairment of goodwill and tradenames in 2020.

■ FY 2021 | Results as indicated at low end of Guidance Range

	2021 Results € million	2020 Results € million	Growth in %	Growth in %cc	Guidance 2021
Revenue	17,619	17,859	(1)	2	Low to mid- single digits cc growth
Net income	969	1,164	(17)	(14)	
Net income excl. special items	1,018	1,359	(25)	(23)	High-teens to mid-twenties cc decline

Results in line with guidance despite unanticipated headwinds


- Significantly higher than expected impact from COVID-19
- Higher than expected wage inflation
- Negative effects from fair value remeasurements

cc = at constant currency

► Special items are effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. FY 2021 excl. effects from FME 25 program (€49 M) | FY 2020 excluding Latin America impairment of goodwill and tradenames (€ 195 M).

■ Dividend Increase to be proposed

Dividend per share in €



- Fundamental business drivers and growth expectations intact despite unprecedented but temporary effects of COVID-19 pandemic

- Striving for dividend continuity and shareholder return

1 Planned dividend proposal for 2021 of €1.35 to be approved by the AGM on May 12, 2022

AGENDA

1 **Strategy Update**

2 **Medical Update**

3 **Business Update**

4 **Financials**

5 **Outlook**

■ Q4 2021 | Positive Revenue Growth

North America

	€ million	
Revenue	3,156	6%
Organic growth		0%

EMEA

	€ million	
Revenue	732	2%
Organic growth		2%

Asia-Pacific

	€ million	
Revenue	552	7%
Organic growth		4%

Latin America

	€ million	
Revenue	195	10%
Organic growth		20%

North America
68%

EMEA
16%

Asia-Pacific
12%

Latin America
4%



- Solid revenue growth of 6% realized
- Organic growth despite significant negative effects of COVID-19 driven by international market

■ Q4 2021 | Organic Growth despite COVID-19 Effects

Revenue	Q4 2021 € million	Q4 2020 € million	Growth in %	Growth in %cc	Organic growth in %	Same market treatment growth in %
Health Care Services	3,621	3,406	6	3	2	(2)
North America	2,872	2,704	6	2	1	(3)
EMEA	359	337	6	6	5	(2)
Asia-Pacific	248	235	5	5	4	3
Latin America	135	125	8	17	20	(2)



Drivers

- + FX translation effects
- + Organic growth despite COVID-19 and lower reimbursement for calcimimetics (in North America)
- + Asia-Pacific with positive same market treatment growth

■ Q4 2021 | Organic Growth in Health Care Products

Revenue	Q4 2021 € million	Q4 2020 € million	Growth in %	Growth in %cc	Organic growth in %
Health Care Products	1,026	994	3	1	1
North America	284	279	2	(2)	(2)
EMEA	373	378	(1)	(1)	(1)
Asia-Pacific	304	282	8	4	4
Latin America	60	52	16	18	18




Drivers

- + FX translation effects
- + Increased sales from machines for chronic treatment
- + Increased sales from Home HD products and in-center disposables
- Lower sales of products for acute care treatments

cc = at constant currency


■ Q4 2021 | Operating Margin Development



Q4 operating income margin drivers

- Inflationary cost increases and higher personnel expense
- Remeasurement effect on the fair value of investments
- Unfavorable effects from COVID-19
- FME25-related costs
- Favorable impact from equity method investees in prior year
- Higher bad debt expense
- + Prior year impairment LA segment
- + Higher reimbursement rate driven by an increased number of patients with Medicare Advantage coverage

■ FY 2021 | Operating Margin Development




Operating income margin drivers

- Inflationary cost increases and higher personnel expense
- Significantly higher negative COVID-19 net effects (including U.S. federal relief funding) than anticipated in guidance
- Remeasurement effect on the fair value of investments
- FME25-related costs
- Higher bad debt expense
- + Prior year impairment Latin America segment
- + Higher reimbursement rate driven by an increased number of patients with Medicare Advantage coverage

pp = percentage points

■ Q4 2021 | Solid underlying Cash Flow Development

	Q4 2021 € million	Q4 2020 € million
Operating cash flow	669	584
In % of revenue	14.4	13.3
Capital expenditures, net	(269)	(301)
Free cash flow	400	283
Free cash flow after investing activities	246	130



Current ratings ³	S&P	Moody's	Fitch	
	Rating	Outlook	Rating	Outlook
BBB	stable	Baa3	stable	BBB-

► 1 See chart 39 for a reconciliation of EBITDA | 2 Excl. U.S. federal relief funding and advanced payments under the CARES Act

3 Latest update: S&P: July 20, 2021; Moody's: May 4, 2021; Fitch: April 9, 2020

AGENDA


1 **Strategy Update**

2 **Medical Update**

3 **Business Update**

4 **Financials**

5 **Outlook**



Headwinds

- **COVID-19 excess mortality**
- **Labor cost increase beyond 3%**
- **Potential U.S. ballot initiative (California)**
- **Macro-economic inflationary environment and elevated supply chain costs**

Expected negative impact on Operating Income

~ € 100 M

~ € 100 M

€ 20 – 30 M

~ € 50 M



Tailwinds

- **Business growth including:**
 - MA mix increase
 - ESRD PPS rate increase
 - Home treatment growth and Value based care
 - Acquisitions
- **PPE cost reduction**
- **FME25 savings**

Expected positive impact on Operating Income



■ 2022 Guidance

Revenue

Low to mid-single digits

(constant currency growth in %¹)

Basis:

2021: € 17,619 M

Net Income

Low to mid-single digits

(constant currency growth in %¹)

Basis:

2021: € 1,018 M

Assumptions:

- COVID-19
 - Accumulated excess mortality to impact operating income by € 100 million compared to the level of 2021
 - Staff shortages are anticipated not to cause significant disruptions in production, distribution and dialysis operations
- Macro-economic inflation and supply chain costs to impact operating income by € 50 million
- Labor costs for 2022 are expected to be around € 100 million in excess of the 3% base wage inflation assumption
- Any potential further government support is assumed to be applied to manage the unprecedented labor market situation if costs exceed the above labor costs assumptions
- FME25 savings are expected to contribute € 40 to 70 million on operating income
- Remeasurement effects on the fair value of investments are expected to be volatile but neutral on a full year basis


Excluding special items:

Special items include costs related to FME25 and other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.

¹ Basis 2021 and Guidance 2022 are exclusive of special items and subject to the assumptions

■ FME25 | Enabling Execution on our Strategy 2025

Framework of FME25 program



¹ Costs are treated as special items and guidance 2022 is exclusive of special items.

■ Mid-term Targets 2020-2025

Revenue

(CAGR, constant currency growth in %)

Mid-single digit

Net Income

(CAGR, constant currency growth in %)

High-single digit

Assumption:

It is assumed that FME25 compensates for the anticipated COVID-19 related effects.

Excluding special items:

Special items include costs related to FME25 and effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.



■ Q4 2021 | Profit and Loss

	Q4 2021 € million	Q4 2020 € million	Growth in %	Growth in %cc
Revenue	4,647	4,400	6	3
Operating income	449	462	(3)	(7)
Operating income margin in %	9.7	10.5		
Operating income excl. special items	492	657	(25)	(28)
Operating income margin in % excl. special items	10.6	14.9		
Net interest expense	67	84	(21)	(24)
Income before taxes	382	378	1	(3)
Income tax expense	79	139	(43)	(46)
Tax rate in %	20.6	36.7		
Non-controlling interest	74	62	22	18
Net income	229	177	29	23
Net income excl. special items	263	372	(29)	(32)

cc = at constant currency


■ FY 2021 | Profit and Loss

	FY 2021 € million	FY 2020 € million	Growth in %	Growth in %cc
Revenue	17,619	17,859	(1)	2
Operating income	1,852	2,304	(20)	(17)
Operating income margin in %	10.5	12.9		
Operating income excl. special items	1,915	2,499	(23)	(21)
Operating income margin in % excl. special items	10.9	14.0		
Net interest expense	280	368	(24)	(22)
Income before taxes	1,572	1,936	(19)	(16)
Income tax expense	353	501	(30)	(27)
Tax rate in %	22.4	25.9		
Non-controlling interest	250	271	(8)	(5)
Net income	969	1,164	(17)	(14)
Net income excl. special items	1,018	1,359	(25)	(23)

cc = at constant currency

■ FY 2021 Services


Revenue	FY 2021 € million	FY 2020 € million	Growth in %	Growth in %cc	Organic growth in %	Same market treatment growth in %
Health Care Services	13,876	14,114	(2)	2	1	(2)
North America	11,020	11,364	(3)	0	0	(3)
EMEA	1,379	1,365	1	2	1	(3)
Asia-Pacific	942	876	7	10	9	5
Latin America	499	485	3	18	17	(1)



cc = at constant currency

■ FY 2021 Products

Revenue	FY 2021 € million	FY 2020 € million	Growth in %	Growth in %cc	Organic growth in %
Health Care Products	3,743	3,745	0	2	2
North America	1,068	1,114	(4)	(1)	(1)
EMEA	1,386	1,398	(1)	0	0
Asia-Pacific	1,068	1,018	5	4	4
Latin America	204	199	2	11	11



cc = at constant currency

■ Debt

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

	FY 2021 € million	FY 2020 € million	FY 2019 € million
Debt			
Short-term debt from unrelated parties	1,178	63	1,150
+ Short-term debt from related parties	78	17	22
+ Current portion of long-term debt	668	1,008	1,447
+ Current portion of long-term lease liabilities from unrelated parties	640	588	622
+ Current portion of long-term lease liabilities from related parties	21	21	17
+ Long-term debt, less current portion	6,647	6,800	6,458
+ Long-term lease liabilities from unrelated parties, less current portion	3,990	3,764	3,960
+ Long-term lease liabilities from related parties, less current portion	98	119	106
Total debt and lease liabilities	13,320	12,380	13,782
– Cash and cash equivalents	(1,482)	(1,082)	(1,008)
Total net debt and lease liabilities	11,838	11,298	12,774

EBITDA

Reconciliation of annualized adjusted EBITDA and net leverage ratio to the most directly comparable IFRS financial measures

	FY 2021 € million	FY 2020 € million	FY 2019 € million
Net income	1,219	1,435	1,439
+ Income tax expense	353	501	402
- Interest income	(73)	(42)	(62)
+ Interest expense	353	410	491
+ Depreciation and amortization	1,586	1,587	1,553
+ Adjustments	125	249	110
Adjusted EBITDA (annualized)	3,563	4,140	3,933
Net leverage ratio (Net debt/EBITDA)	3.3	2.7	3.2

 Adjustments: Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (2021: €13 M), non-cash charges, primarily related to pension expense (2021: €49 M; 2020: €50 M), impairment loss (2021: €38 M; 2020: €199 M), and costs related to the FME25 program (2021: €25 M).


■ 2021 Base for Targets 2022, Reconciliation Adjustments

	FY 2021 € million	Q1 2021 € million	Q2 2021 € million	Q3 2021 € million	Q4 2021 € million
Revenue	17,619	4,210	4,320	4,441	4,647
Net income excl. special items	1,018	251	225	279	263

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

	Q4 2021 € million	Q4 2020 € million
Revenue	4,647	4,400
Net income	229	177
Special item: costs relating to FME25	34	
Special item: LA impairment		195
Net income excl. special items	263	372

■ Return on Invested Capital (ROIC)



- Long-term value creation based on accretive acquisitions and organic growth
- 2018 positive impact from Sound divestiture
- 2019 negative impact from NxStage acquisition
- 2020 negative impact from Latin America impairment
- 2021 negative impact from FME25

➤

- For the years 2015-17 ROIC as reported within the Form 20-F.
- ROIC adjusted in 2018 for the divestiture of Care Coordination activities, FCPA-related charge, U.S. Ballot Initiatives, U.S. tax reform / including these effects, ROIC for FY 2018 was 12.4%
- ROIC adjusted in 2019 for the effects of IFRS 16, NxStage, FCPA, Cost optimization costs, divestiture of Care Coordination activities / including these effects, ROIC for FY 2019 was 6.8% (excl. IFRS 16)
- ROIC in 2020 excl. the impact of the Latin America impairment (special item) and in 2021 excluding FME25 (special item)
- ROIC for 2020 and 2021 was 7.5% and 5.5% excl. IFRS 16 and excl. Latin America impairment in 2020

■ Exchange Rates, U.S. Dialysis Days per Quarter, Definitions

Exchange rates

	FY 2021	FY 2020	FY 2019
€:USD	Period end	1.133	1.227
	Average	1.182	1.142
€:CNY	Period end	7.195	8.023
	Average	7.628	7.875
€:RUB	Period end	85.300	91.467
	Average	87.153	82.725
€:ARS	Period end	116.780	102.900
	Average	112.522	81.042
€:BRL	Period end	6.310	6.374
	Average	6.378	5.894
			4.516
			4.413

U.S. Dialysis Days per quarter

	Q1	Q2	Q3	Q4	Full year
2022	77	78	79	79	313
2021	77	78	79	79	313
2020	77	78	79	79	313
2019	76	78	79	80	313
2018	77	78	78	80	313
2017	77	78	79	79	313
2016	78	78	79	79	314
2015	76	78	79	79	312

DEFINITIONS

cc	At constant currency
HD	Hemodialysis
PD	Peritoneal dialysis
Net income	Net income attributable to shareholders of FME
LTM	Last-Twelve-Months

■ Patients, Treatments, Clinics

	Patients as of Dec. 31, 2021	Treatments as of Dec. 31, 2021	Clinics as of Dec. 31, 2021		Patients as of Dec. 31, 2020	Treatments as of Dec. 31, 2020	Clinics as of Dec. 31, 2020
North America	209,291	32,334,280	2,695		210,260	32,843,592	2,639
Growth in %	0	(2)	2		0	2	2
EMEA	65,599	9,885,319	821		66,008	10,189,373	804
Growth in %	(1)	(3)	2		0	1	3
Asia-Pacific	33,760	4,766,472	405		33,106	4,660,875	400
Growth in %	2	2	1		0	2	0
Latin America	36,775	5,885,816	250		37,179	5,881,415	249
Growth in %	(1)	0	0		7	9	6
Total	345,425	52,871,887	4,171		346,553	53,575,255	4,092
Growth in %	0	(1)	2		0	3	2

■ Financial Calendar 2022

Reporting Dates & AGM

May 4	Q1 2022 Earnings Release and Conference Call
May 12	Annual General Meeting
August 2	Q2 2022 Earnings Release and Conference Call
November 1	Q3 2022 Earnings Release and Conference Call

Conferences & Expert Calls

February 23	Citi - 2022 Healthcare Conference
March 1	Credit Suisse - 2022 Global Health Care Conference
March 15	Oppenheimer Annual Healthcare Conference
March 16	Barclays - Global Healthcare Conference 2022
March 29	Exane BNP Paribas – 3 rd MedTech CEO Conference 2022
April 7	Barclays - 2022 Conversations with the C-Suite with Rice Powell, CEO



Please note that dates and/or participation might be subject to change

■ Contacts

FME INVESTOR RELATIONS

Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany

TICKER:
FME or FMS (NYSE)

WKN:
578 580

ISIN:
DE00057858002

DR. DOMINIK HEGER

Head of Investor Relations, Strategic Development & Communications | EVP

+49(0) 6172-609-2601
dominik.heger@fmc-ag.com

ALICIA CAHILL

Senior Manager
Investor Relations

+1 860-609-2394
alicia.cahill@fmc-ag.com

ROBERT ADOLPH

Vice President
Investor Relations

+49(0) 6172-609-2477
robert.adolph@fmc-ag.com